Register entry
- Registered sites
- 2
- Active NDC listings
- 0
- Live patents
- 6
- Countries
- 1
- Base
- Japan
Authorisation
Registered operations
Analytical testing2Active ingredient (API) manufacture1Finished drug manufacture1
Sites
Registered establishments
2| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| SUCAMPO PHARMA LIMITED LIABILITY COMPANYRegistrant: Sucampo Pharma Americas, LLC | 6-7-6, MINATOJIMAMINAMIMACHI, CHUO-KU KOBEHAIBURIDDOBIJINESUSENTA, KOBE, Hyogo 650-0047, Japan (JPN) | Analytical testing | 3009036781691314841 |
| SUCAMPO PHARMA LIMITED LIABILITY COMPANYRegistrant: Sucampo Pharma Americas, LLC | 4-1, TECHNOPARK, SANDA, Hyogo 669-1339, Japan (JPN) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3004520523718192151 |
Exclusivity
Patents and exclusivities
6| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8338639 | AMITIZAlubiprostone | product | Jan 2027 |
| 8779187 | AMITIZAlubiprostone | product | Jan 2027 |
| 8026393 | AMITIZAlubiprostone | product | Oct 2027 |
Compare
Comparable companies in Japan
- Sumitomo Pharma Co., Ltd.2 sites · 24 NDC
- TAYCA CORPORATION2 sites · 22 NDC
- Hisamitsu Pharmaceutical Co., Inc.2 sites · 16 NDC
- Bushu Pharmaceuticals, Ltd.2 sites · 11 NDC
- ASO Pharmaceutical Co. Ltd.2 sites · 10 NDC
- Lead Chemical Co., Ltd.2 sites · 7 NDC
- SUMITOMO OSAKA CEMENT CO., LTD.2 sites · 6 NDC
- MicroBiopharm Japan Co., Ltd.2 sites · 2 NDC
- Nipro Pharma Corporation2 sites · 2 NDC
- Nissui Corporation2 sites · 2 NDC
Enquiry
Common questions
- Is Sucampo Pharma Americas, LLC FDA approved?
- Sucampo Pharma Americas, LLC holds 2 FDA-registered establishments in Japan. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Sucampo Pharma Americas, LLC's drugs manufactured?
- The FDA register lists KOBE; SANDA. Registered operations: analytical testing, active ingredient (API) manufacture, finished drug manufacture.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.